ArticleFrontiers in oncology2025
Case Report: Fatal myocarditis and myasthenia gravis induced by immune checkpoint inhibitors: concurrent dual adverse events in an older adult.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of metastatic renal cell carcinoma (RCC), offering significant survival benefits. Their use, however, can come at the expense of severe immune-related adverse events (irAEs) involving the myocardium and nervous system. We report an 86-year-old male with relapsed clear cell RCC (Fuhrman grade 3, pT3aN0M0) who developed concurrent myocarditis and myasthenia gravis (MG) after receiving Pembrolizumab and Axitinib for multifocal mediastinal relapse. Despite early initiation of high-dose IV methylprednisolone within 24 hours, the patient's condition deteriorated rapidly, resulting in pneumonia, acute kidney injury requiring hemodialysis, and death. This case highlights the fulminant course of ICI-induced myocarditis and MG, underscoring the importance of prompt recognition, immediate initiation of corticosteroids and IV immunoglobulin, and early consideration of second-line immunomodulatory therapies in severe cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.